Paolo Tarantino: From no anti-HER2 drugs to a plethora of emerging options

Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on Twitter/X:

“From no anti-HER2 drugs to a plethora of emerging options: promising days for targeting HER2+ colorectal cancer with TKIs, mAbs and ADCs. Check out our review on HER2+ CRC, just out in the first issue of ESMO-GI!”